Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20400492 | 0.90 | SLC6A2 (0.32) | LMNASMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19031049 | 0.80 | CAMK2A (0.37) | DPP4LMNASMN1; SMN2 | |
| SCHEMBL1812652 | 0.79 | ESR2 (0.39) | LMNASMN1; SMN2THRBALDH1A1MAPT | |
| SCHEMBL1812651 | 0.79 | ESR2 (0.39) | LMNASMN1; SMN2THRBALDH1A1MAPT | |
| SCHEMBL19031254 | 0.74 | ALDH1A1 (0.36) | LMNASMN1; SMN2ALDH1A1MAPTNPSR1 | |
| SCHEMBL9692780 | 0.71 | SLC6A2 (0.31) | LMNASLC6A2SLC6A4SLC6A3THRB | |
| SCHEMBL22543476 | 0.68 | ESR2 (0.31) | — | |
| SCHEMBL8727375 | 0.67 | — | — | |
| SCHEMBL8727371 | 0.67 | — | — | |
| SCHEMBL16620652 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6410486-B2 | FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-25 | — | — | US | disclosed |
| US-20020019422-A1 | Cycloalkylalkanecarboxamides and their preparation and use | WETTERICH FRANK (DE) | 2002-02-14 | — | — | US | disclosed |
| US-6265447-B1 | FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019422-A1 | Cycloalkylalkanecarboxamides and their preparation and use | CBR3, CYCS, CBR1 | DPP4 4508/4885LMNA 1204/4885SMN1; SMN2 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.